scleroderma: state of the art management
TRANSCRIPT
![Page 1: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/1.jpg)
Mary E. Strek, MDProfessor of Medicine
University of Chicago Medicine
Scleroderma: State of the Art Management
April 16, 2016
![Page 2: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/2.jpg)
Pulmonary Complications of Scleroderma
Common and under recognized May not track with other manifestations Impair quality of life May masquerade as “idiopathic” disease
- Forme fruste (incomplete or atypical form)
- Presenting manifestation
- Lung dominant or limited
MAY BE TREATABLE!
![Page 3: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/3.jpg)
Pulmonary Complications in CTDDisease Antibody Airway ILD Vascular Pleural
RA RF, aCCP Bronchiolitis, Bronchiectasis
UIP Secondary Effusions
SLE ANA, dsDNA, Smith Bronchiolitis Not common
PrimaryAlveolar Hemorrhage
Effusions
Scleroderma ANA, Scl-70Anticentromere (PAH)
Rare fNSIPUIP
SecondaryPrimary
Rare
MCTD ANA, RNP Notcommon
fNSIP PrimarySecondary
Notcommon
DM/PM ANA, SS-A, Jo-1Myositis panel
Rare OPNSIPUIPDAD
Secondary Rare
Sjogren’s ANA, SS-A, SS-B Bronchiectasis NSIPLIPUIP
Secondary Notcommon
![Page 4: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/4.jpg)
Systemic Sclerosis (SS): Classification Criteria
- Definite SS ≥ 9
Van den Hoogen, Ann Rheum Dis 2013;72:1747
![Page 5: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/5.jpg)
Systemic Sclerosis Sine Scleroderma
Originally described 40 years ago Uncommon variant of limited scleroderma
- No sclerodactyly but skin thickening/digital edema
- Interstitial lung disease in > 80%
Positive ANA > 93% Non-specific interstitial pneumonia (NSIP)
![Page 6: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/6.jpg)
Puffy digits
6
![Page 7: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/7.jpg)
Systemic Sclerosis Sine Scleroderma
Fischer, CHEST 2006;130:976
![Page 8: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/8.jpg)
Systemic Sclerosis Sine Scleroderma
![Page 9: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/9.jpg)
Scleroderma: Pulmonary Manifestations
Interstitial lung disease (ILD) is very common Esophageal dysfunction and aspiration Pulmonary HTN alone and with ILD Airway disease
- Obstructive lung disease (follicular bronchiolitis)
Pleuritis Pulmonary “scar” carcinoma Restriction of chest wall or respiratory muscle weakness
![Page 10: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/10.jpg)
Scleroderma: Phenotypes
Solomon Eur Resp Rev 2013;22:6-19Wigley, Mayo Clin Proc 2013; 88:377-393
Interstitial Lung Disease Pulmonary Hypertension
Pathogenesis Activation of lung fibroblasts pulmonary fibrosis
Injury to vascular endothelium arterial fibrosis
Prevalence 40-75% PFTs90% CT
13-35% ECHO7-13% RHC
Associated with Antitopoisomerase I (SCL-70) Anticentromere
Cause of death in SSc 35% 30%
Compared to idiopathic ILD SSc-ILD improved survival SSc-PH worse survival
![Page 11: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/11.jpg)
Scleroderma Associated ILD Physical exam/labs
- Clubbing uncommon/Raynaud’s phenomenon frequent- anti-Scl-70 antibody correlates with ILD (seen 1/3rd)
Pulmonary function abnormalities- Decreased TLC in 32 – 67% patients- Decreased FVC in up to 77% patients- Decreased DLCO in 90%
Major histopathologic patterns- NSIP most common (56% vs 72% vs 76%)- Most cases fibrotic (vs cellular) NSIP- UIP pattern (honeycombing on HRCT)
![Page 12: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/12.jpg)
Scleroderma: Fibrotic NSIP
![Page 13: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/13.jpg)
Scleroderma: Fibrotic NSIP
![Page 14: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/14.jpg)
Cellular NSIP
![Page 15: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/15.jpg)
Cellular NSIP
![Page 16: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/16.jpg)
Slide courtesy of Aliya Husain, MD.
Cellular NSIP
![Page 17: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/17.jpg)
Scleroderma ILD: Prognosis Progresses to severe ILD in 15% May be rapidly progressive in 1st 2 years
- HRCT with ground-glass opacities
- PFT’s show decline in FVC or diffusing capacity
Gradual decline in lung function or stable disease in others ILD may affect survival
- PFT’s predictive
- Prognosis may be better if NSIP noted on biopsy
![Page 18: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/18.jpg)
Scleroderma ILD: Whom to Treat?
Solomon Eur Resp Rev 2013;22:6-19
![Page 19: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/19.jpg)
Scleroderma ILD: Whom to Treat?
Goh AJRCCM 2008;177:1248
![Page 20: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/20.jpg)
Scleroderma: Mild Disease
1999 2003
![Page 21: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/21.jpg)
Scleroderma: Extensive ILD
![Page 22: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/22.jpg)
Scleroderma ILD: Treatment
Vij, CHEST 2013;143:1-11
![Page 23: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/23.jpg)
Cyclophosphamide (Cytoxan)
Potent but toxicity limits long-term use Nitrogen mustard like alkylating agent Progressive reduction in B and T lymphocytes 500 to 750 mg/m2 BSA IV then monthly bolus May increase dose up to 1 g/m2 BSA Decrease dose renal insufficiency
Marder, Semin Respir Crit Care Med 2007; 28:398-417
![Page 24: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/24.jpg)
Cyclophosphamide MAJOR TOXICITY: Bone marrow, hemorrhagic cystitis
(can be fatal) Hydration! Urine output > 100 mL/h In ICU may need catheter drainage and bladder irrigation OTHER TOXICITIES: Infection, infertility, pulmonary,
Cancers (bladder, cervix, skin, leukemia) MONITOR: CBC, renal function and UA weekly then every
2 weeks, periodic LFT’s Urine cytology and PAP smears annually
![Page 25: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/25.jpg)
Scleroderma Lung Study Double-blind, randomized placebo controlled trial
Effect of oral cyclophosphamide (CYC) vs placebo
Study design:
- Scleroderma and dyspnea
- Restriction on PFT’s (FVC 45-85%/DLCO >30% predicted)
- Inflammatory ILD on BAL or ground-glass on HRCT
- CYC 2mg/kg/day (average dose 100mg) or placebo for 1 year
- 2nd year follow-up OFF therapy
- Primary end-point FVC at 12 months
Conducted by NIH at 13 centers
Tashkin, NEJM 2006; 354:2655
![Page 26: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/26.jpg)
Scleroderma Lung Study Results:
- Screened 267 pts, 158 randomized
- Baseline characteristics matched; disability score lower placebo
- 54 pts in CYC and 55 in placebo completed study
Mean adjusted absolute difference in FVC at 12 months 2.53% (95% CI, 0.28 to 4.79%) favoring CYC (P<0.03)
Adverse events greater in CYC group (hematuria, leukopenia, anemia, pneumonia) and 3 malignancies (bladder, vulvar, angiosarcoma scalp)
![Page 28: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/28.jpg)
Mycophenolate Mofetil (CellCept)
Potent and well tolerated Inhibits critical enzyme in purine synthesis in activated lymphocytes Starting dose 500 mg BID, target dose 1000 mg BID Great variability serum levels in patients on same dose TOXICITIES: GI, Infections, Leukopenia less common Lower rate side effects: hospitalizations, GI, infections, amenorrhea If GI toxicity: decrease dose, more freq intervals (TID) MONITOR: CBC after dose change then monthly EXPENSIVE so insurance may not cover TERATOGENIC/PREGNANCY CATEGORY X
Marder, Semin Respir Crit Care Med 2007; 28:398-417
![Page 29: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/29.jpg)
Mycophenolate in Scleroderma
Fischer, J Rheumatol 2013; 40:640-646
![Page 30: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/30.jpg)
Mycophenolate in Scleroderma
Fischer, J Rheumatol 2013; 40:640-646
![Page 31: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/31.jpg)
Azathioprine (Imuran)
Less potent and slower onset of action cyclophosphamide Metabolized to purine antagonist 6-mercatopurine Inhibits both cellular and humoral immunity Starting dose 50 mg daily,1.5-2 mg/kg (maximum 200 mg)
daily Low thiopurine methotransferase level increase risk BM
toxicity TOXICITIES: Bone marrow, liver, infection, cancer? MONITOR: CBC, LFTs after dose change then monthly
Marder, Semin Respir Crit Care Med 2007; 28:398-417
![Page 32: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/32.jpg)
• Nintedanib– Tyrosine kinase inhibitor– DOSE 150 mg BID, can reduce to 100 mg BID– MONITOR Liver function monthly x 3 mos then Q 3 mos
• Pirfenidone– Antifibrotic effects– DOSE 267 mg TID x 2 weeks, then 534 mg TID x 2 weeks,
then 801 mg TID– MONITOR Liver function monthly x 6 mos then Q 3 mos
Overview FDA approved IPF Meds
![Page 33: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/33.jpg)
Efficacy Data: Nintedanib in IPF
NEJM 2014;370:2071-82
![Page 34: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/34.jpg)
Adverse EffectsDRUG ADVERSE EFFECT DOSE MODIFICATION ADDITIONAL
MEASURESNINTEDANIB Diarrhea Reduce dose Imodium
N/abdominal pain Reduce dose/food PPI, H2 blocker
Arterial thrombosis Caution in high risk cardiovascular disease
Monitor for cardiac events
Elevated LFTs Reduce or interrupt dose Monitor LFTs
DRUG INTERACTIONS
Ketoconazole, Emycin, carbamazepine, phenytoin, rifampin
Avoid with anticoagulants?
PIRFENIDONE N/V/anorexia Reduce dose/food PPI, H2 blocker
Rash HOLD drug Avoid sunlight
Elevated LFTs Reduce or interrupt dose Monitor LFTs
Agranulocytosis STOP DRUG Monitor CBC?
DRUG INTERACTIONS
Fluvoxamine Avoid Ciprofloxacin
![Page 35: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/35.jpg)
Scleroderma Associated Pulm HTN Often unrelated to ILD Risk factors- Raynaud’s, limited scleroderma,
anticentromere Ab PFT’s
- FVC 80% predicted- DLCO 40%predicted
Often severe- HFpEF common- High frequency pericardial disease- Echo may not correlate- Treatment responsive
![Page 36: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/36.jpg)
GERD: Its Role
Lee, Am J Med 2010;123:304-311
![Page 37: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/37.jpg)
GERD: Management Weight loss if obese
Elevate head of bed
Avoid eating 2-3 hrs before lying down
Eliminate foods (caffeine, ETOH etc) that trigger reflux
Proton pump inhibitor 30-60 min before first meal day
Prokinetic agent
Nissan fundoplication often not an option due to dysmotility
Katz, Am J Gastroenterol 2013; 108:308-328
![Page 38: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/38.jpg)
Monitoring
INFECTION, INFECTION, INFECTION!
![Page 39: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/39.jpg)
Scleroderma Chronic multisystem autoimmune disease
Variable clinical course
Includes mild and subtle disease
Minority have significant interstitial lung disease
Treat BEFORE irreversible organ damage occurs
Wigley, Mayo Clin Proc 2013; 88:377-393
![Page 40: Scleroderma: State of the Art Management](https://reader035.vdocuments.site/reader035/viewer/2022070512/5889effb1a28ab32458b6a3b/html5/thumbnails/40.jpg)
And Don’t Forget!
Infection
Pulmonary Embolism
Medication toxicity
Cigarette smoking related complications
Environmental and occupational exposures